Broadcast on Nymox AlzheimAlert Test Now Available for Viewing Through the Nymox Web Site.

Business Editors, Health/Medical Writers

MAYWOOD, NJ--(BW HealthWire)--June 28, 2001

Nymox Pharmaceutical Corporation (NASDAQ: NYMX) is pleased to announce that the American Medical Review broadcast profiling its AlzheimAlert(TM) test is now available for viewing through a direct link from the company's web site at www.nymox.com.

AlzheimAlert(TM) is Nymox's state of the art aid to the diagnosis of Alzheimer's disease. AlzheimAlert(TM) uses urine samples to detect the levels of a brain protein called neural thread protein known to be elevated in patients with Alzheimer's disease. Nymox offers AlzheimAlert(TM) as laboratory test service for physicians at a cost of $295 through its certified Clinical Reference Laboratory in Maywood, New Jersey.

The Associated Press has also featured a story on Nymox and AlzheimAlert(TM). The report included the experiences of Dr. James Bischoff, a primary-care physician in Montana, with his use of AlzheimAlert(TM) in his practice. The article quoted Dr. Bischoff as being "extremely happy" with the test's accuracy and the reassurance it provides and as saying that "there's a lot of family doctors in small towns all across the country that can be benefit from this." The story reported that Dr. Bischoff had two patients who were wrongly diagnosed elsewhere with Alzheimer's disease but who had normal AlzheimAlert(TM) results. These patients improved dramatically when Dr. Bischoff found the right treatment for them.

American Medical Review features technologies that have significantly contributed on a national and/or international level to the advancement of the nation's healthcare. AMR airs on Public Television stations and the American Independent Network (AIN) nation-wide as well as internationally on WorldNet, a U.S. Government News and Information service.

The Associated Press is the oldest and largest news organization in the world, serving 1,700 newspapers in the U.S. It provides news services for more than one billion people a day worldwide.

Nymox has several major proprietary drug development programs with candidate drugs for Alzheimer's disease and other indications. In the area of Alzheimer's disease, Nymox has made a number of key discoveries about the link between spherons and Alzheimer's disease which have led to the development of spheron-based potential therapeutics for this fatal disease. Another Nymox major drug discovery platform targets neural thread protein, the brain protein detected by Nymox's AlzheimAlert(TM) test and implicated in the Alzheimer's disease process. Nymox also has several antibacterials in development, including potential treatments for E. coli 0157 food contamination, and other antibacterials for urinary tract infections and staph and strep infections. The Company's R&D pharmaceutical pipeline also includes candidate drugs for other indications in development. Nymox's second proprietary marketed product, NicAlert(TM), is available in the U.S. and Japan. NicAlert(TM) is an inexpensive, simple-to-use test strip that uses urine or saliva to determine whether a person is using tobacco products. It is currently being used in studies of tobacco use and exposure across the U.S. and marketed as a test to determine whether a person, such as a teenager, student athlete or insurance applicant, is using a tobacco product.

Nymox Pharmaceutical Corporation has facilities in Maywood, NJ and Montreal. Its stock is traded on NASDAQ with the symbol NYMX. More information is available at http://www.nymox.com/.

This press release contains certain "forward-looking statements" as defined in the United States Private Securities Litigation Reform Act of 1995 that involve a number of risks and uncertainties. There can be no assurance that such statements will prove to be accurate and the actual results and future events could differ materially from management's current expectations. Such factors are detailed from time to time in Nymox's filings with the United States Securities and Exchange Commission.